Daratumumab monotherapy is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.
|31/05/2016||14/06/2016||Full Pharmacoeconomic Evaluation Recommended|
|27/10/2016||13/03/2017||The cost effectiveness of daratumumab (Darzalex®) monotherapy has not been demonstrated. Therefore it is not recommended for reimbursement.|
The HSE has approved reimbursement following confidential price negotiations; April 2018.